Urinary C-C-motif chemokine ligand 14 (CCL-14) was recently introduced as a predictor of persistent AKI and renal replacement therapy in a patient cohort with stage 2–3 CSA-AKI. This evidence concerns the gene CCL14 and acute kidney injury.